HojnikMGeorgeJZiporenLShoenfeldY. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation1996; 93: 1579–1587.
2.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
3.
MottramPMGelmanJS. Mitral valve thrombus mimicking a primary tumor in the antiphospholipid syndrome. J Am Soc Echocardiogr2002; 15: 746–748.
4.
KrauseILevSFraserA. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis2005; 64: 1490–1493.
5.
PengoVRuiz-IrastorzaGDenasGAndreoliLKhamashtaMTincaniA. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’. Autoimmun Rev2012; 11: 577–580.
6.
KhamashtaMACuadradoMJMujicFTaubNAHuntBJHughesGR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995; 332: 993–997.
7.
Ruiz-IrastorzaGCuadradoMJRuiz-ArruzaI. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus2011; 20: 206–218.
8.
SalzbergSPNemirovskyDGoldmanMEAdamsDH. Aortic valve vegetation without endocarditis. Ann Thorac Surg2009; 88: 267–269.
9.
O'NeillDMagaldiJDobkinsDGrecoT. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome. Arch Intern Med1995; 155: 325–327.
10.
AgirbasliMAHansenDEByrdBF3rd. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr1997; 10: 877–880.
